Symbiosis Pharmaceutical Services is opening an office in North America to support biopharma companies with its vial-filling services, including liquid and lyophilized formulations in injectable dosage forms.
 
The company will open a commercial site in Cambridge, MA, to support clients on both the East and West Coast, as well as provide a base for reaching new customers in this region. The company is currently recruiting to expand its U.S. commercial team.
 
Colin MacKay, chief executive officer at Symbiosis Pharmaceutical Services, said, “Given Cambridge is the epicentre of the global biotech community, it is the ideal location for us to open an office in the US.  Back in 2015, we made the decision to strategically focus on the North American market after we identified a surge in funding for early stage biotech companies, which are exactly the type of drug development company that are best suited to seek our manufacturing scale and specialist capabilities.”
 
Mr. MacKay added, “At a macro level, demand for biologic and highly potent products is likely being driven by the increased emphasis on the development of treatments for small patient populations in the case of orphan indications, new oncology products requiring containment capabilities and novel tailored personalised medicines. Those kind of products require specific GMP manufacturing skills for the small-scale production of sterile batches for clinical trials, hence the clear uptake in demand for what we do at Symbiosis.”